Clinical trials: sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Cancer
A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics
To study the pharmacokinetic characteristics of TQ-B3234 in the human body, recommend a reasonable regimen for subsequent research.
- Trial name
- NCT02996838
- Testing
- TQ-B3234
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Metastatic Colorectal Cancer
Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)
The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with metastatic colorectal cancer refractory to standard chemotherapies.
- Trial name
- ALTER0703 (NCT02332499)
- Testing
- Anlotinib
- Where
- 29 sites in China
- Volunteers
- 419 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease
A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients
To evaluate the safety and pharmacokinetics of different dose roflumilast in China COPD patient.
- Trial name
- NCT02671942
- Testing
- Roflumilast
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Small Cell Lung Cancer
Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)
To compare the effects and safety of Anlotinib with placebo in patients with small cell lung cancer(SCLC).
- Trial name
- NCT03059797
- Testing
- Anlotinib
- Where
- 12 sites in China
- Volunteers
- 120 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Solid Tumors
Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients
The purpose of this study is to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer patients.
- Trial name
- NCT02622932
- Testing
- Anlotinib and 14C-labeled Anlotinib
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Hepatitis B
Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B
The purpose of this study is to evaluate the safety and efficacy of Domestic Tenofovir Disoproxil Fumarate Tablets in Chinese patients with hepatitis B ,compared with Tenofovir Disoproxil Fumarate Tablets of Gilead.
- Trial name
- NCT02287857
- Testing
- Domestic Tenofovir Disoproxil Fumarate Tablets, Tenofovir Disoproxil Fumarate Tablets of Gilead
- Where
- 15 sites in China
- Volunteers
- 360 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Type 2 Diabetes
Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.
Bioequivalence Study of Empagliflozin Tablets and Jardiance® Under Fasting and Fed Conditions in Chinese Healthy Volunteers.
- Trial name
- NCT03771781
- Testing
- Empagliflozin Tablets, Empagliflozin Tab 25 MG
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Hepatitis b
Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers
A single-center, open-Label, randomized, single-dose, two-period, two-sequence, crossover study to assess the bioequivalence of test formulation entecavir tablets 1.0 mg with reference formulation entecavir tablets (Baraclude®)…
- Trial name
- NCT03847246
- Testing
- Baraclude® tablets,1.0 mg, Entecavir tablets,1.0 mg
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Nasopharyngeal Carcinoma
Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma
This is a Phase III randomized controlled multi-center trial comparing anlotinib plus Gemcitabine/Cisplatin with placebo plus Gemcitabine/Cisplatin in previous untreated patients with recurrent/metastatic Nasopharyngeal…
- Trial name
- NCT03601975
- Testing
- Gemcitabine/Cisplatin
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pharmacokinetic
Pharmacokinetic and Tolerance Study of TQ-A3326 in Healthy Participants.
To study the single dose and multi-doses pharmacokinetic characteristics and tolerance of TQ-A3326 in the human body；To study the transformation of TQ-A3326；To study the effect of the food on the pharmacokinetic characteristics…
- Trial name
- NCT03714568
- Testing
- TQ-A3326
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gastroenteropancreatic Neuroendocrine Tumor G3
A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3
To assess the primary effects and safety of Anlotinib in patients with Gastroenteropancreatic Neuroendocrine Tumor G3.
- Trial name
- NCT03457844
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Asthma
Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma
assess the efficacy and safety of Salmeterol Xinafoate and Fluticasone Propinate Powder for inhalation (50ug/250ug) in combination with seretide to patients with Asthma.
- Trial name
- NCT03461627
- Testing
- Salmeterol Xinafoate and Fluticasone Propinate Powder, Seretide
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Tumor
Tolerance and Pharmacokinetics of TQB2450
To study the pharmacokinetic characteristics of TQB2450 in the human body, recommend a reasonable regimen for subsequent research.
- Trial name
- NCT03460457
- Testing
- TQB2450
- Volunteers
- 50 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-hodgkin's Lymphoma
Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma
Primary Outcome Measures: Area under the curve (AUC) forTQB2303 and rituximab concentrations [ Time Frame: 85 days ] Secondary Outcome Measures: The Maximum Concentration (Cmax) of the TQB2303 and rituximab [ Time Frame: 85 days…
- Trial name
- NCT03456466
- Testing
- TQB2303, Rituximab
- Where
- 2 sites in China
- Volunteers
- 122 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Tumor
Tolerance and Pharmacokinetics of TQ-B3233
Study of Tolerance and Pharmacokinetics of TQ-B3233 Capsule, phase I,single arm.
- Trial name
- NCT03453034
- Testing
- TQ-B3233
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Cancer
A New Drug Used for Advanced Cancer
To identify the safety and tolerance of TQ-B3203.
- Trial name
- NCT03447145
- Testing
- TQ-B3203
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Renal Cell Carcinoma
Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy
Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
- Trial name
- NCT02072044
- Testing
- Anlotinib
- Where
- 15 sites in China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Hepatitis B
Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B
The purpose of this study is to evaluate the safety and efficacy of Entecavir maleate tablets in Chinese patients with hepatitis B
- Trial name
- NCT01926288
- Testing
- Entecavir maleate tablets, blank Baraclude tablets, Blank maleate entecavir tablets
- Where
- 9 sites in China
- Volunteers
- 287 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gastric Cancer
Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Gastric Cancer.
- Trial name
- NCT02461407
- Testing
- Anlotinib
- Where
- 38 sites in China
- Volunteers
- 378 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Cancer
A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics
A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics.To further study the pharmacokinetic characteristics of Anlotinib in the human body, recommend a reasonable regimen for subsequent research.
- Trial name
- NCT02752516
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.